Specialty Pharmacy

Pharmacy leaders can be equipped to make effective decisions to support a successful work experience, regardless of work setting.

FDA approves rituximab (Rituxan) plus chemotherapy for pediatric patients with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia.

Payton Nyquvest, CEO and founder of Numinus, discussed the laboratory development and regulatory side of psychedelic research.

Ibrutinib in combination with venetoclax shows promise in patients with previously untreated chronic lymphocytic leukemia.

Affordability in drug pricing can be addressed by bringing the manufacturer and plan sponsor to negotiate costs and determine fair compensation for product and service providers in the supply chain.

The diagnostic tool widens the age group of individuals who can get tested and can be used in conjunction with a mammogram.

Approximately half of people with HCV don't know they're infected, mainly because they have no symptoms.

Although specialty therapies have the potential to help people live healthier lives, their cost and complexity can create distinct challenges.

Miglustat (Zavesca) is indicated for the treatment of mild to moderate type I Gaucher disease.

Chronic HBV increases the risk of developing liver failure, liver cancer, and cirrhosis.

Ray Tancredi, RPh, MBA, divisional VP of specialty pharmacy development and brand Rx/vaccine purchasing at Walgreens, provides an analysis and overview of key specialty pharmaceuticals in development.

Lomecel-B (Longeveron) is an investigational allogeneic, bone marrow-derived medicinal signaling cell medication that is being evaluated in a phase 2 trial.

Ray Tancredi, RPh, MBA, divisional VP of specialty pharmacy development and brand Rx/vaccine purchasing at Walgreens, discusses key drugs in development that are slated to launch in 2022.

Ocrelizumab is indicated for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive disease, in adults.

Are you curious about what other pharmacists earn? About the job satisfaction and compensation of pharmacists in other geographic areas? So are we!

Investigators have developed an immunotherapy that is a potential option for children with hard-to-treat brain cancer.

Ten quiz questions to assess your knowledge on common symptoms and treatments for HIV.

The study’s identification of a network of possible candidate genes to carefully control for mutations could alter the future clinical implementation of CRISPR.

The Build Back Better bill include an authorization for the government to negotiate lower drug prices.

Pembrolizumab demonstrated a statistically significant improvement in disease-free survival, reducing the risk of disease recurrence or death by 32% compared to placebo.

Olumiant shows favorable long-term safety profile in rheumatoid arthritis.

Pharmacists should keep an eye on the pipeline for autologous and allogeneic CAR T-cell therapies as well as antibody-specific treatments.

Pharmacy performance measures can support greater patient access to care and services through team-based care and to facilitate value-based contracts between pharmacists and payers.

Risk factors for liver cancer include chronic infection with hepatitis B or hepatitis C virus, cirrhosis, diabetes, and non-alcoholic fatty liver disease.

Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, discusses the implications of research into the treatment of liver metastases in patients with gastrointestinal NETs.

Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, discusses the findings regarding the efficacy of combining and sequencing liver-directed therapy with systemic therapy.

Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, discusses areas of concern when approaching the combination and sequencing of liver-directed therapy with systemic therapy.

Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, discusses the potential sequencing in the combination of liver-directed therapy with systemic therapy.

Specialty pharmacists give physicians and specialists the opportunity to focus less on non-medical issues and more on the patient and efficiently finding the most optimal therapy.

Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, discusses the results of combining liver-directed therapy with systemic therapy when treating patients with gastrointestinal neuroendocrine tumors.